Quantcast

Latest Lupus erythematosus Stories

2009-01-09 11:50:00

ANN ARBOR, Mich., Jan. 9 /PRNewswire/ -- A study published today in The Journal of Occupational and Environmental Medicine (http://tinyurl.com/9x2ebc) found that the mean annual price tag for lupus - including medical expenditures, absence from the job, and short-term disability costs - was nearly $20,000 per patient. The mean cost climbed to more than $60,000 per patient when lupus was accompanied by the kidney disease nephritis, as it often is. That's more than the average annual cost...

2008-10-27 15:00:09

SAN FRANCISCO, Oct. 27 /PRNewswire-FirstCall/ -- UCB (Euronext Brussels: UCB) announced data from two randomized controlled trials showing that treatment with epratuzumab a humanized anti-CD22 antibody, resulted in clinically meaningful reduced disease activity, improved health-related quality of life (HRQoL) measurements and reduced reliance on corticosteroids compared to placebo treatment in patients with active moderate and severe systemic lupus erythematosus (SLE). These findings were...

2008-08-26 12:01:27

DENVER, Aug. 26 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (BULLETIN BOARD: CONX) , a worldwide developer and marketer of diagnostic test kits, has announced its collaboration with BG Medicine (BGM) http://www.bg-medicine.com/, a Waltham, Mass.-based life sciences company focused on the discovery, development and commercialization of novel molecular-based diagnostics. Under the collaboration, Corgenix' AtherOx(R) products will be included in studies conducted by BG Medicine to...

2008-08-15 09:00:21

Medarex has announced that its partner MedImmune has initiated a Phase IIa multi-dose clinical trial of MEDI-545 for the potential treatment of systemic lupus erythematosus. MEDI-545 is a fully human antibody generated by Medarex's UltiMAb Human Antibody Development System. Under the terms of the agreement, Medarex will receive a milestone payment of an undisclosed amount. The Phase IIa clinical trial is designed to evaluate the safety and tolerability of multiple subcutaneous dose...

2008-08-12 12:00:34

GAITHERSBURG, Md., Aug. 12 /PRNewswire/ -- MedImmune today announced that it has initiated enrollment in a Phase 2A trial with an investigational human monoclonal antibody (MAb) targeting interferon-alpha in patients with systemic lupus erythematosus (SLE or lupus). The study is designed to assess the safety and tolerability of the antibody, also known as MEDI-545 in patients with moderately to severely active lupus, despite standard of care. Current treatment options for moderately to...

2008-07-21 12:01:26

Hadasit Bio-Holdings, a subsidiary of Hadasit, has announced that one of its portfolio companies, Verto, has successfully completed a human clinical trial of a device for treating patients who suffer from systemic lupus erythematosus. The goals of the trial at the Hadassah Medical Center in Ein Kerem, in which ten lupus patients took part, were to demonstrate the safety and efficacy of the Lupusorb, developed by Verto. The treatment was successful and achieved the goals. Verto is said to...

2008-07-21 08:45:08

Hadasit Bio-Holdings, (HBL) a subsidiary of Hadasit (the technology transfer company of the Hadassah - Hebrew University Medical Center), which is traded on the Tel Aviv Stock Exchange under the symbol HDST, announced today that one of its portfolio companies, Verto (in which it has a 75% stake), has successfully completed a human clinical trial of a device for treating patients who suffer from systemic lupus erythematosus. The goals of the trial at the Hadassah Medical Center in Ein...

2008-07-03 15:00:10

Chinese scientists say a treatment using several drugs targeting various parts of the immune system helps patients with severe lupus involving the kidneys. In our study, multitarget therapy is shown to be superior to traditional therapy for inducing complete remission of class V+IV lupus nephritis, with few side effects, said Dr. Lei-Shi Li of the University School of Medicine in Nanjing, China. Lupus nephritis is inflammation of the kidneys occurring in patients with systemic lupus...

4f0fbec980b76eb1b28575c8292452a61
2008-01-21 10:28:09

WINSTON-SALEM, N.C. -- An international consortium of scientists has identified multiple genes that are linked to systemic lupus erythematosus, a devastating autoimmune disease that affects between 1 million and 2 million Americans. Reporting in Nature Genetics, the scientists also confirmed earlier findings linking lupus to several other genes "“ highlighting the role that genetics plays in the disease. "These findings underscore that numerous genes, which are often...

2008-01-17 15:35:00

Findings pinpoint numerous proteins as potential autoimmune disease targetsThe lupus-suppressing action is the result of what is known as a nonsense mutation of the Coronin-1A gene (Coro1a) required for the development of the disease. A nonsense mutation causes the gene to produce proteins that no longer function. The Coronin-1A gene is a multifunctional regulator of the cytoskeleton, a network of protein fibers or filaments in the cell that helps maintain cell shape and is the key...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related